Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05903131 · ClinicalTrials.gov registry record · Phase 2
Uterine Preservation Via Lifestyle Transformation
A Phase 2 study of Endometrial Hyperplasia and Grade 1 Endometrial Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 3
- Study locations
NCT05903131: Recruiting Phase 2 study of Endometrial Hyperplasia and Grade 1 Endometrial Cancer, sponsored by Washington University School of Medicine.
NCT05903131 is a Phase 2 study of Endometrial Hyperplasia and Grade 1 Endometrial Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05903131, a Phase 2 study of Endometrial Hyperplasia and Grade 1 Endometrial Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 3
- Study locations
Study Summary
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced usual care
- BEHAVIORAL Telemedicine behavioral weight intervention
- DRUG Progestin
- DRUG Levonorgestrel-releasing IUD.
Study Locations (3)
Missouri
- Washington University School of Medicine - St Louis
New Mexico
- University of New Mexico - Albuquerque
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 2 |
What NCT05903131 shows while recruiting
NCT05903131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 2 conditions, with Endometrial Hyperplasia appearing as the primary indexed condition, and to 4 interventions - of which Enhanced usual care is the first listed.
NCT05903131 reports a single indexed study location in Missouri, New Mexico, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05903131 about?
NCT05903131 is a clinical study titled "Uterine Preservation Via Lifestyle Transformation". Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in in...
What is the current status of trial NCT05903131?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2024-10-24. Estimated completion is 2029-10-31.
What conditions does trial NCT05903131 study?
This clinical trial studies the following conditions: Endometrial Hyperplasia, Grade 1 Endometrial Cancer.
What interventions are being tested in trial NCT05903131?
The interventions under investigation include: Enhanced usual care (BEHAVIORAL), Telemedicine behavioral weight intervention (BEHAVIORAL), Progestin (DRUG), Levonorgestrel-releasing IUD. (DRUG).
Who is sponsoring clinical trial NCT05903131?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05903131 being conducted?
This trial has 3 study locations across Missouri, New Mexico, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05903131's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI